Compare Stocks: CNSP, PTPI, UG, and MIRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$5.84	$5.44	$1.90 ▼ $10.59	$8.53M	3.06	8,813 shs	18,542 shs
MIRA MIRA Pharmaceuticals	$0.77	$0.81	$0.60 ▼ $2.45	$32.52M	1.52	1.59 million shs	105,525 shs
PTPI Petros Pharmaceuticals	$0.01	$0.00	$0.00 ▼ $0.03	$193K	1.95	109,862 shs	6,089 shs
UG United-Guardian	$7.17	$7.27	$5.58 ▼ $8.45	$32.91M	0.96	7,927 shs	4,263 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	0.00%	+0.85%	+5.80%	+23.21%	-20.97%
MIRA MIRA Pharmaceuticals	0.00%	+1.31%	-0.82%	-16.97%	-46.63%
PTPI Petros Pharmaceuticals	0.00%	+3.33%	+129.63%	+1.64%	-77.86%
UG United-Guardian	0.00%	+0.42%	+0.28%	+2.14%	-8.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$5.84	$5.44	$1.90 ▼ $10.59	$8.53M	3.06	8,813 shs	18,542 shs
MIRA MIRA Pharmaceuticals	$0.77	$0.81	$0.60 ▼ $2.45	$32.52M	1.52	1.59 million shs	105,525 shs
PTPI Petros Pharmaceuticals	$0.01	$0.00	$0.00 ▼ $0.03	$193K	1.95	109,862 shs	6,089 shs
UG United-Guardian	$7.17	$7.27	$5.58 ▼ $8.45	$32.91M	0.96	7,927 shs	4,263 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	0.00%	+0.85%	+5.80%	+23.21%	-20.97%
MIRA MIRA Pharmaceuticals	0.00%	+1.31%	-0.82%	-16.97%	-46.63%
PTPI Petros Pharmaceuticals	0.00%	+3.33%	+129.63%	+1.64%	-77.86%
UG United-Guardian	0.00%	+0.42%	+0.28%	+2.14%	-8.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNSP CNS Pharmaceuticals	1.00	Sell	N/A	N/A
MIRA MIRA Pharmaceuticals	2.00	Hold	N/A	N/A
PTPI Petros Pharmaceuticals	0.00	N/A	N/A	N/A
UG United-Guardian	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest CNSP, PTPI, UG, and MIRA Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/20/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	UG United-Guardian	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/17/2026	CNSP CNS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	UG United-Guardian	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
6/24/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	$7.29 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.04	N/A	N/A	$4.04 per share	0.00
UG United-Guardian	$10.55M	3.12	$0.48 per share	14.88	$2.44 per share	2.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNSP CNS Pharmaceuticals	-$15.85M	-$23.59	N/A	N/A	N/A	N/A	-204.25%	-141.87%	11/18/2026 (Estimated)
MIRA MIRA Pharmaceuticals	-$10.44M	-$1.24	N/A	N/A	N/A	N/A	-106.95%	-104.18%	12/2/2026 (Estimated)
PTPI Petros Pharmaceuticals	-$8.16M	-$0.36	N/A	N/A	N/A	N/A	-78.22%	-23.50%	12/2/2026 (Estimated)
UG United-Guardian	$2.11M	$0.54	13.28	N/A	N/A	22.01%	22.24%	19.12%	N/A

Latest CNSP, PTPI, UG, and MIRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	CNSP CNS Pharmaceuticals	-$0.24	-$0.38	-$0.14	-$0.38	N/A	N/A
8/12/2026	Q2 2026	MIRA MIRA Pharmaceuticals	N/A	-$0.03	N/A	-$0.03	N/A	N/A
8/7/2026	Q2 2026	UG United-Guardian	N/A	$0.16	N/A	$0.16	N/A	$3.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$0.60	8.37%	-5.11%	111.11%	1 Years

Latest CNSP, PTPI, UG, and MIRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/14/2026	UG United-Guardian		$0.30	8.19%	7/28/2026	7/28/2026	8/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNSP CNS Pharmaceuticals	N/A	5.86	5.86
MIRA MIRA Pharmaceuticals	N/A	200.08	200.08
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
UG United-Guardian	N/A	7.32	6.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNSP CNS Pharmaceuticals	14.02%
MIRA MIRA Pharmaceuticals	35.16%
PTPI Petros Pharmaceuticals	12.34%
UG United-Guardian	23.16%

Insider Ownership

Company	Insider Ownership
CNSP CNS Pharmaceuticals	1.82%
MIRA MIRA Pharmaceuticals	19.89%
PTPI Petros Pharmaceuticals	12.25%
UG United-Guardian	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNSP CNS Pharmaceuticals	5	1.46 million	1.43 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	42.02 million	33.66 million	Not Optionable
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
UG United-Guardian	20	4.59 million	3.26 million	Not Optionable

CNSP, PTPI, UG, and MIRA Headlines

Recent News About These Companies

UG Q2 Earnings Rise Y/Y on Strong Cosmetic Ingredient Sales

August 14, 2026 | zacks.com

United-Guardian: Q2 Earnings Snapshot

August 7, 2026 | wtop.comW

United-Guardian Reports Second Quarter Results

August 7, 2026 | globenewswire.com

United-Guardian Insider Trading Activity | NASDAQ:UG | Benzinga

July 16, 2026 | benzinga.com

United-Guardian Declares Cash Dividend

July 16, 2026 | globenewswire.com

UG Outperforms Industry in 6 Months: Buy, Sell or Hold the Stock?

July 8, 2026 | zacks.com

Engages Danayi Capital Corp. To Provide Digital Marketing Services

June 12, 2026 | thenewswire.comT

Upside Gold Corp. Announces Closing of $5 Million Brokered Private Placement

June 12, 2026 | thenewswire.comT

Upside Gold Corp. Announces Closing of $5 Million Brokered Private Placement

June 12, 2026 | thenewswire.comT

Upside Gold Announces Fully Permitted Drill Program at the Kena Gold-Copper Project

May 27, 2026 | thenewswire.comT

United-Guardian Q1 Earnings Rise Y/Y on Strong Renacidin Demand

May 18, 2026 | zacks.com

United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

May 13, 2026 | seekingalpha.com

Upside Gold Corp. Finalizes Acquisition of Strategic High-Grade Gold Claims Adjacent to the Kena Project

May 13, 2026 | thenewswire.comT

United-Guardian Reports First Quarter Results

May 8, 2026 | globenewswire.com

Upside Gold Corp. Signs LOI For Strategic Claims Adjacent To The Kena Property

April 27, 2026 | thenewswire.comT

Upside Gold Corp. Announces Grant Of Stock Options

April 9, 2026 | thenewswire.comT

United-Guardian 2025 Earnings Fall Y/Y Amid Weak Sales Trends

March 31, 2026 | zacks.com

United-Guardian: Q4 Earnings Snapshot

March 27, 2026 | khou.comK

United-Guardian Reports 2025 Financial Results

March 27, 2026 | globenewswire.com

Consumer staples names with highest dividend yield amid Middle East war crisis

March 9, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CNSP, PTPI, UG, and MIRA Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

$5.84 0.00 (0.00%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$5.75 -0.09 (-1.61%)

As of 04:00 AM Eastern

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

MIRA Pharmaceuticals NASDAQ:MIRA

$0.77 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.76 -0.02 (-2.17%)

As of 07:29 AM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Petros Pharmaceuticals NASDAQ:PTPI

$0.0062 0.00 (0.00%)

As of 09/11/2026 12:14 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

United-Guardian NASDAQ:UG

$7.17 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$7.15 -0.02 (-0.28%)

As of 09/11/2026 04:10 PM Eastern

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNSP, PTPI, UG, and MIRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNSP, PTPI, UG, and MIRA Earnings

Compare Dividends

Latest CNSP, PTPI, UG, and MIRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNSP, PTPI, UG, and MIRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNSP, PTPI, UG, and MIRA Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

MIRA Pharmaceuticals NASDAQ:MIRA

Petros Pharmaceuticals NASDAQ:PTPI

United-Guardian NASDAQ:UG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools